Skip to content
The Policy VaultThe Policy Vault

lenalidomide — Medica

Myelodysplastic syndrome

Initial criteria

  • age ≥ 18 years
  • Patient has symptomatic anemia OR transfusion-dependent anemia OR anemia not controlled with an erythropoiesis-stimulating agent OR patient has myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasm with SF3B1 mutation and thrombocytosis

Approval duration

1 year